Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences is set to potentially disrupt the cell and gene therapy industry with its proprietary gene circuit platform and its lead candidate SENTI-202 showing promising results in clinical trials. In addition, its identification of a donor phenotype that correlates with improved outcomes could further boost efficacy and increase adoption of its therapy. However, there are risks to consider, such as regulatory uncertainties and the potential need for additional financing which could result in share dilution for shareholders.

Bears say

Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for cancers using its gene circuit platform, with its leading candidate SENTI-202 targeting CD33 and FLT3 for Acute Myeloid Leukemia (AML). Their recent financing deal raises concern for future dilution, while their logic-gated off-the-shelf CAR-NK cell therapy's complicated manufacturing and significant competition in the cell therapy space present challenges to their promising initial data for SENTI-202 and their overall potential commercial success, leading to a negative outlook for the company's stock.

SNTI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Holdings Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 3 analysts, SNTI has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Holdings Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.